9 research outputs found

    Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts

    Get PDF
    At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial “A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial”

    Get PDF
    An online meeting of experts held on November 6, 2020 describes the results of EMPA-REG OUTCOME and EMPEROR-Reduced trials on sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. We analyzed cardiovascular and renal outcomes in patients with and without type 2 diabetes (T2D) receiving empagliflozin. A number of proposals and recommendations have been adopted regarding the further study of the cardiovascular and renal effects of empagliflozin and its practical use in patients with heart failure, regardless of the T2D presence

    Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

    Get PDF
    International audienc

    Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide

    No full text
    corecore